gsk1120212

Trametinib (GSK1120212) is a MEK inhibitor that inhibits MEK1 and MEK2 (IC50=0.7/0.9 nM) with ATP non-competitive and oral activity. Trametinib activates autophagy and induces apoptosis.

Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) is a highly potent and selective MEK inhibitor that specifically inhibits MEK1/2 (IC50: 2 nM).

Trametinib-D4 is the deuterated form of Trametinib. Trametinib (T2125) (GSK1120212; JTP-74057) is an orally bioavailable MEK inhibitor, effectively inhibiting MEK1 and MEK2 with an IC50 of 2 nM. Additionally, Trametinib (T2125) can activate autophagy and induce apoptosis.

Trametinib-13C6 is a 13C labeled version of Trametinib. Trametinib (T2125) (GSK1120212; JTP-74057) is an orally active MEK inhibitor with IC50 values of 2 nM for MEK1 and MEK2. It has the capability to activate autophagy and induce apoptosis.